Charles Russell Speechlys advises shareholders of Prescient Financial Intelligence on sale to Quilter Private Client Advisers
Charles Russell Speechlys has advised the shareholders of Prescient Financial Intelligence Limited on the sale of the company to Quilter Private Client Advisers. This acquisition by Quilter Private Client Advisers, the third recent takeover for the company, adds more than £800m of assets under advice to Quilter.
Prescient is an independent financial adviser firm that offers bespoke financial planning advice, operating from offices in Exeter, Glasgow, London and York. Over the years, Prescient has developed a client-focused practitioner team built on the strength of its past experience. The deal marks a new chapter for Prescient - the managing director of Prescient, Chris Woodhams, retired alongside the firm's director of risk, Hugh Bance, with 23 staff, including eight financial advisers and three trainee advisers joining Quilter Private Client Advisers' existing regional offices.
Chris Woodhams, former managing director of Prescient, commented: "Many thanks to Andrew Clarke, Charlie Ring and the rest of the team at Charles Russell Speechlys for their continued support throughout this transaction, who guided us all through the legal intricacies of the deal, aided by the team's financial services sector expertise and invaluable commercial insight."
Andrew Clarke, Corporate Partner who led the deal alongside Corporate Senior Associate Charlie Ring, commented: "We were delighted to advise the shareholders on this sale, where we were able to utilise our financial services expertise to provide commercial as well as legal support throughout the transaction. We wish the Prescient team and Quilter every success for the future."
The Charles Russell Speechlys team, led by Andrew Clarke and Charlie Ring included Svetlana Kisyova (Corporate Associate), Sarah Morley and Martin Fisher (Real Estate) and Robert Birchall and Andrew Priestly (Corporate Tax).
News & Insights
Charles Russell Speechlys advises Emergex Vaccines on $11m fundraising
Emergex is a UK-based biotechnology company and pioneers of developing synthetic ‘set point’ vaccines .
Public Company Update - November 2020
The November 2020 edition of our biannual Public Company Update.